



Points to Consider in Remote and Hybrid GMP/GDP Inspections



Points to Consider in Remote and Hybrid GMP/GDP Inspections Team

Authors and Contributors

Inspections Subteam

Alexandre Drapier, GlaxoSmithKline (Co-lead Author)
Gabriele Gori, GlaxoSmithKline (Co-lead Author)
Tor Gråberg, AstraZeneca (Co-lead Author)
David Chesney, DL Chesney Consulting
Eser Earley, Astellas
Laura Singer, Heron Therapeutics
Prashant Wange, Sun Pharmaceutical Industries Ltd.

Technology Subteam

Raghu Ram Pannala, PhD, Sciegen (Subteam Lead)
William Cashin, CordenPharma
Siegfried Schmitt, PhD, Parexel
Herbert Vail, Shionogi, Inc.

Legal/Survey Subteam

David Chesney, DL Chesney Consulting
Felicia Ford-Rice, Parexel
Ruth K. Miller, JD, Parenteral Drug Association

Task Force

Tiffany Baker, ValSource (Co-lead)
Eva Urban, CSL Behring (Co-lead)
Karin Baer, NeuroDerm
William Cashin, CordenPharma
David Chesney, DL Chesney Consulting
Robert Dana, Elkhorn Associates
Alexandre Drapier, GlaxoSmithKline
Eser Earley, Astellas
Felicia Ford-Rice, Parexel
Gabriele Gori, GlaxoSmithKline
Tor Gråberg, AstraZeneca

Ghada Haddad, PhD, Merck
Alexander Nezlin, UroGen Pharma
Raghu Ram Pannala, PhD, Sciegen
Siegfried Schmitt, PhD, Parexel
Vishal Sharma, Vi'enni Training and Consulting
Michele Simone, Bracco
Laura Singer, Heron Therapeutics
Prashant Wange, Sun Pharmaceutical Industries Ltd.
Herbert Vail, Shionogi, Inc.
Bryan Wilson, GlaxoSmithKline

Acknowledgements

The authors express their gratitude to Ewan Norton, Lead Senior GMDP Inspector, Medicines and Healthcare Products Regulatory Agency, United Kingdom, and Teo Seok Hui, Senior Regulatory Specialist (GMP Auditor), Health Sciences Authority, Singapore, for their valuable insights and feedback.

Points to Consider in Remote and Hybrid GMP/GDP Inspections

ISBN: 978-1-945584-28-2
© 2021 Parenteral Drug Association, Inc.
All rights reserved.



Table of Contents

INTRODUCTION	1	Topic D.1: Responding to Requests	24
Scope	2	Topic D.2: Sharing Audit Reports.....	25
Glossary.....	2	Topic D.3: Sample Collection.....	26
I. PLANNING AND NOTIFICATION OF A REMOTE INSPECTION	4	Topic E.1: Use of Daily or Intermediate Wrap-ups	27
Topic A.1: Types of Inspections Performed Remotely ...	4		
Topic B.1: Notification.....	5		
Topic B.2: Verification of an Inspector's Identity.....	6		
Topic C.1: Remote Inspection Team Formation	7		
Topic C.2: Planning the Agenda	9		
Topic D.1: Hardware Requirements.....	11		
Topic D.2: Planning to Share Information.....	13		
Topic D.3: Planning for Effective Use of Technology ...	15		
Topic D.4: Pre-Inspection Agreements	16		
Topic E.1: Preparing Necessary Documents.....	17		
Topic E.2: Sharing of Inspection Reports.....	18		
Topic E.3: Timelines for Sharing Documentation.....	19		
II. REMOTE INSPECTION REALIZATION.....	20		
Topic A.1: Use of Real-Time Interactions	20		
Topic B.1: Managing Multiple Workstreams.....	22		
Topic C.1: Inspector Access to Systems	23		
III. REMOTE INSPECTION CLOSING, CONCLUSION, AND RESPONSE.....	28		
Topic A.1: Knowing an Inspection Has Ended.....	28		
Topic A.2: Inspection Report and Findings and Response.....	29		
Topic A.3: Issuance of GMP/GDP Certificate.....	30		
Topic B.1: Frequency of Reinspection.....	31		
IV. REFERENCES.....	32		
V. RELEVANT GLOBAL GUIDANCES.....	33		
VII. APPENDIX 1: LIST OF QUALITY DOCUMENTS TO BE REVIEWED DURING INSPECTION	34		
VIII. APPENDIX 2: 2021 PDA RESEARCH: GLOBAL INDUSTRY RESPONSES TO REMOTE REGULATORY INSPECTIONS	36		
Survey Methodology	36		
Survey Results	37		
Survey Conclusion	59		

FIGURES AND TABLES INDEX

Figure 1 Flow of the Sections of this Points to Consider Document

Table A1-1 Documents That May Be Requested by an Inspector.....



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org